<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-18_00-49-41</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Mixed ovarian germ cell tumour (dysgerminoma‑predominant) post right adnexectomy and 2 BEP cycles, with a shrinking but indeterminate 1.8 cm left ovarian surface nodule and incomplete staging, organ-function, and fertility information.

Core Treatment Strategy:
- Do not modify systemic‑therapy plan or schedule further cycles until FIGO stage, staging completeness, and organ function are clarified.
- Arrange unified post‑BEP restaging: contrast CT/MRI abdomen–pelvis ± chest plus whole‑body PET/FAPI to assess left nodule and extrapelvic disease.
- Request pathology addendum to provide full staging details (tumour size, capsule/surface, washings, extraovarian disease, FIGO stage, teratoma maturity).
- Implement standardized serial tumour markers (AFP, β‑hCG, LDH, CA125, NSE) and document renal, pulmonary, marrow status and fertility goals to guide chemo vs fertility‑sparing surgery.

Change Triggers:
- If imaging/PET shows active left implant or additional disease, prioritize completion/optimization of systemic therapy and consider non‑fertility‑sparing surgery.
- If imaging/PET shows no active disease and markers normalize, consider limited fertility‑sparing surgery or surveillance rather than intensifying chemotherapy.
- If organ‑function assessment reveals significant BEP toxicity, de‑escalate or switch systemic approach and increase reliance on surgical/local control.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>无性细胞瘤合并畸胎瘤成分化疗2程：2024.8.23 AFP:15.84 CA125:44.12024.09.02外院腔镜手术切除右侧卵巢+输卵管，术后病理：卵巢恶性肿瘤，结合免疫组化诊断为：无性细胞瘤合并畸胎瘤成分（占比约10%），伴局部坏死及血管增生。血常规肝肾功能一般可MR（2024.09.27）：右卵巢切除术后，左侧卵巢外后方占位，请结合临床。盆腔少量积液。2024.9.28 CT: 盆腔占位术后2024.09 亮丙瑞林1次2024.09.27 CA125(糖类抗原CA125):36.10U/ml↑ NSE(神经元特异烯醇化酶):19.60ng/ml↑ 其余无殊BEP方案化疗2程:BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3，q21d，末次2024.10.23亮丙瑞林皮下注射病理会诊咨询意见:2430975、2430966及2430967：（右附件）卵巢混合性生殖细胞肿瘤，以无性细胞瘤成分为主，合并少量成熟性畸胎瘤成分；输卵管慢性炎。免疫组化结果（HI24-45014）：SALL4（+），Oct4（+），PLAP（+），D2-40（+），GPC-3（-），AFP（-），ZBTB16（-），EMA（-），CD30（-），CD117（+），Ki-67（+约80％）2024.10.22 AFP &lt;2咨询病理及后续诊疗，预约MRI体格检查: 一般可影像复片: MR复片：左侧卵巢表面实性结节灶（1.8cm），较前缩小，需警惕种植，建议FAPI。</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;2 cycles&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[&quot;BEP方案化疗2程:BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3，q21d&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;2 (2024-10-22)&quot;,&quot;CA125&quot;:&quot;36.10 (2024-09-27)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Post right oophorectomy; received 2 cycles BEP; left ovarian surface nodule noted, under imaging evaluation&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;畸胎瘤成分&quot;],&quot;histology&quot;:&quot;无性细胞瘤合并畸胎瘤成分&quot;,&quot;laterality&quot;:&quot;Right&quot;,&quot;primary&quot;:&quot;Ovarian mixed germ cell tumor&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;2&quot;,&quot;end_date&quot;:&quot;2024-10-23&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3, q21d&quot;,&quot;start_date&quot;:&quot;2024-08-23&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Yes&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2024-10-23&quot;,&quot;evidence&quot;:&quot;BEP方案化疗2程:BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3，q21d，末次2024.10.23&quot;,&quot;evidence_type&quot;:&quot;Clinical&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2024-08-23&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;Unknown&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;SCENE&quot;:&quot;Frontline_PDS_or_NACT_IDS&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2024-09-02&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Laparoscopic right ovary + salpingectomy&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2024-08-23&quot;,&quot;description&quot;:&quot;Start BEP chemotherapy (2 cycles)&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;AFP 15.84; CA125 44.1&quot;,&quot;regimen_or_test&quot;:&quot;BEP方案化疗: BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3, q21d&quot;},{&quot;date&quot;:&quot;2024-09-02&quot;,&quot;description&quot;:&quot;Laparoscopic right ovary + salpingectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Pathology: 卵巢恶性肿瘤, 无性细胞瘤合并畸胎瘤成分&quot;,&quot;regimen_or_test&quot;:&quot;Pathology performed&quot;},{&quot;date&quot;:&quot;2024-09-27&quot;,&quot;description&quot;:&quot;MRI: post-right oophorectomy, left adnexal/posterior to left ovary mass; small pelvic effusion&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Left ovarian extra-surface mass noted&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2024-09-28&quot;,&quot;description&quot;:&quot;CT pelvis post-op showing pelvic mass&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Postoperative pelvic mass&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2024-09&quot;,&quot;description&quot;:&quot;亮丙瑞林 1 time (subcutaneous injection)&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;亮丙瑞林&quot;},{&quot;date&quot;:&quot;2024-10-22&quot;,&quot;description&quot;:&quot;AFP measurement&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;AFP &lt;2&quot;,&quot;regimen_or_test&quot;:&quot;AFP&quot;},{&quot;date&quot;:&quot;2024-10-23&quot;,&quot;description&quot;:&quot;Last BEP administration (documented last dose)&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration 2024-10-23&quot;,&quot;regimen_or_test&quot;:&quot;BEP&quot;}]},&quot;VISIT_DATE&quot;:&quot;2024-10-29&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;2024-10-23&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2024-08-23&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;15.84&quot;},{&quot;date&quot;:&quot;2024-10-22&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;&lt;2&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2024-10-22&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;&lt;2&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/mL&quot;},{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2024-08-23&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;44.1&quot;},{&quot;date&quot;:&quot;2024-09-27&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;36.10&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2024-09-27&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;36.10&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;NSE&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2024-09-27&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;19.60&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2024-09-27&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;19.60&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2024-08-23&quot;,&quot;description&quot;:&quot;Start BEP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2024-09-02&quot;,&quot;description&quot;:&quot;Laparoscopic right ovary + salpingectomy&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2024-10-23&quot;,&quot;description&quot;:&quot;Last documented BEP administration&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2024-09-27&quot;,&quot;description&quot;:&quot;MRI showing left ovarian mass&quot;,&quot;type&quot;:&quot;Imaging&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;2 cycles completed&quot;,&quot;last_admin_date&quot;:&quot;2024-10-23&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3, q21d&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;无性细胞瘤成分&quot;,&quot;畸胎瘤成分&quot;],&quot;date&quot;:&quot;2024-09-02&quot;,&quot;diagnosis&quot;:&quot;卵巢恶性肿瘤，结合免疫组化诊断为：无性细胞瘤合并畸胎瘤成分（占比约10%），伴局部坏死及血管增生。病理会诊：卵巢混合性生殖细胞肿瘤，以无性细胞瘤成分为主，合并少量成熟性畸胎瘤成分；输卵管慢性炎。&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;Oct4&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PLAP&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;D2-40&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;GPC-3&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;AFP&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;EMA&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;CD30&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;CD117&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;(+约80％)&quot;}],&quot;involvement_sites&quot;:[],&quot;laterality&quot;:&quot;Right&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;术后病理：卵巢恶性肿瘤，结合免疫组化诊断为：无性细胞瘤合并畸胎瘤成分（占比约10%），伴局部坏死及血管增生。病理会诊（右附件）：卵巢混合性生殖细胞肿瘤，以无性细胞瘤成分为主，合并少量成熟性畸胎瘤成分；输卵管慢性炎。免疫组化：SALL4（+），Oct4（+），PLAP（+），D2-40（+），GPC-3（-），AFP（-），ZBTB16（-），EMA（-），CD30（-），CD117（+），Ki-67（+约80％）&quot;,&quot;sample_type&quot;:&quot;Resection&quot;,&quot;site&quot;:&quot;Right adnexa&quot;,&quot;tumor_size&quot;:&quot;Unknown&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Stage not provided&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;FAPI&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Left ovary&quot;,&quot;Pelvis&quot;],&quot;date&quot;:&quot;2024-09-27&quot;,&quot;findings&quot;:[&quot;Post-right oophorectomy; left adnexal/posterior to left ovary mass&quot;,&quot;Small pelvic effusion&quot;],&quot;impression&quot;:&quot;Left-sided adnexal extra-surface mass; consider implantation&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2024-09-28&quot;,&quot;findings&quot;:[&quot;Postoperative pelvic mass&quot;],&quot;impression&quot;:&quot;Pelvic postoperative change with residual mass&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Left ovary&quot;],&quot;date&quot;:&quot;Unknown&quot;,&quot;findings&quot;:[&quot;Left ovarian surface solid nodule 1.8cm, decreased in size compared with prior&quot;],&quot;impression&quot;:&quot;Left ovarian surface solid nodule 1.8cm; decreased; suspect implantation; recommend FAPI&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Improved&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2024-08-23&quot;,&quot;description&quot;:&quot;Start BEP chemotherapy (2 cycles)&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;AFP 15.84; CA125 44.1&quot;,&quot;regimen_or_test&quot;:&quot;BEP方案化疗: BLM 15mg d1-3 +DDP 30mg d1-3+ VP-16 0.1g d1-3, q21d&quot;},{&quot;date&quot;:&quot;2024-09-02&quot;,&quot;description&quot;:&quot;Laparoscopic right ovary + salpingectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Pathology: 卵巢恶性肿瘤, 无性细胞瘤合并畸胎瘤成分&quot;,&quot;regimen_or_test&quot;:&quot;Pathology performed&quot;},{&quot;date&quot;:&quot;2024-09-27&quot;,&quot;description&quot;:&quot;MRI: post-right oophorectomy, left adnexal/posterior to left ovary mass; small pelvic effusion&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Left ovarian extra-surface mass noted&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2024-09-28&quot;,&quot;description&quot;:&quot;CT pelvis post-op showing pelvic mass&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Postoperative pelvic mass&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2024-09&quot;,&quot;description&quot;:&quot;亮丙瑞林 1 time (subcutaneous injection)&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;亮丙瑞林&quot;},{&quot;date&quot;:&quot;2024-10-22&quot;,&quot;description&quot;:&quot;AFP measurement&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;AFP &lt;2&quot;,&quot;regimen_or_test&quot;:&quot;AFP&quot;},{&quot;date&quot;:&quot;2024-10-23&quot;,&quot;description&quot;:&quot;Last BEP administration (documented last dose)&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration 2024-10-23&quot;,&quot;regimen_or_test&quot;:&quot;BEP&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before deciding on further chemotherapy versus interval conservative surgery, we must first obtain complete staging details, updated cross‑sectional imaging, and full tumour marker panel including β‑hCG and LDH with toxicity assessment post‑BEP.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please arrange and report comprehensive contrast-enhanced CT/MRI of abdomen–pelvis (±chest) to fully characterize the left ovarian surface nodule and search for peritoneal/extra‑pelvic disease; clarify timing/feasibility of planned FAPI/PET study.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>We need a detailed summary of the initial specimen: tumor size, capsule/surface status, teratoma maturity, margins, and any extraovarian involvement to support accurate FIGO staging.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>Confirm indication, protocol, and timing for FAPI/PET (or alternative PET) to assess metabolic activity of the left ovarian lesion and detect occult implants; results will directly influence systemic versus surgical strategy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Systemic therapy decisions are limited by unclear FIGO stage and uncertain nature of the left ovarian lesion; prioritizing completion of staging information and updated imaging is critical before committing to more cycles or additional surgery in this fertility-sparing case.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>We need updated contrast-enhanced CT/MRI of abdomen–pelvis (±chest) with detailed characterization of the left ovarian surface nodule and any peritoneal/implant disease to determine if current therapy remains appropriate or if surgery should be escalated.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>Please provide full staging pathology details (FIGO stage, capsule/surface involvement, washings, omentum/biopsies, nodes, teratoma maturity, margins) to clarify risk and guide adjuvant intensity vs surgery timing.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>Confirm feasibility and timing of PET or FAPI-PET to assess metabolic activity of the left ovarian lesion and exclude occult extra-pelvic disease, which will influence further systemic therapy and fertility-sparing strategy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Current imaging shows a 1.8 cm left ovarian surface nodule decreasing in size, but there is no up‑to‑date whole‑abdomen/chest imaging or PET/FAPI to confirm extent of disease or fully characterize this lesion; updated cross‑sectional and, if available, metabolic imaging are needed before making further surgical or systemic decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>A decreasing 1.8 cm solid nodule on the left ovarian surface remains suspicious for implantation; no PET/FAPI or whole‑body metabolic study is documented, so feasibility and timing of FAPI‑PET (or equivalent) should be clarified for disease characterization and staging.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Pathology and IHC confirm pure dysgerminoma plus mature teratoma without yolk sac elements; please update full staging details (capsule/surface, peritoneal/omentectomy, nodes, washings, margins, FIGO stage) so we can judge whether the left ovarian nodule represents possible implantation versus benign/secondary change.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>radiologist</td><td>Given mixed germ cell histology with normalized AFP but uncertain stage, we need detailed re-evaluation of the left ovarian surface nodule (size trend, enhancement, diffusion, relation to cortex and peritoneum) and any peritoneal/omental implants on current cross-sectional imaging.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>Metabolic characterization of the left ovarian surface nodule is still completely absent; please confirm if PET/FAPI is planned and timing relative to ongoing chemotherapy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>Given the unresolved 1.8 cm left ovarian surface lesion and unknown extra‑pelvic status, please advise on optimal timing and modality for PET/FAPI integration with planned cross‑sectional imaging.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Systemic-therapy planning remains constrained by uncertain FIGO stage, uncharacterized left ovarian surface lesion, and absent organ-function/toxicity data; further chemotherapy beyond two cycles should be deferred until pathology, imaging, and fertility goals are clarified.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>From an imaging workflow perspective, pairing PET/FAPI with the next contrast-enhanced CT or MRI abdomen–pelvis once the current chemotherapy cycle is completed (or just before major surgical decisions) would best characterize the 1.8 cm left ovarian surface lesion and detect extra‑pelvic disease in a single staging timepoint.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before committing to further chemotherapy cycles, we need full staging details, updated cross-sectional imaging, and a clear statement of the patient’s fertility priorities to balance systemic therapy versus delayed conservative surgery.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please provide a detailed re-evaluation of the left ovarian surface nodule and peritoneum on updated contrast CT/MRI, and confirm feasibility/timing of combined CT/MRI plus PET/FAPI as a single staging timepoint post‑BEP.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>Kindly issue an addendum clarifying tumour size, capsule/surface involvement, washings, any extraovarian disease, teratoma maturity, and an assigned FIGO stage if possible.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>We need your plan for PET/FAPI: optimal timing relative to recent BEP, protocol details, and how best to integrate it with same‑day CT/MRI for comprehensive staging of the left ovarian lesion and any implants.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>nuclear</td><td class='mono'>chair</td><td>I propose whole‑body FDG‑PET (or FAPI if available) scheduled with the next contrast CT/MRI after completion of the current BEP cycle, using a standard oncologic protocol (vertex–mid‑thigh, low‑dose CT for attenuation) to metabolically characterize the left ovarian surface nodule and detect any peritoneal/extra‑pelvic implants in a single staging session.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Mixed ovarian germ cell tumour post-right adnexectomy and 2 BEP cycles; left ovarian surface nodule now decreasing on MRI.  \n- Clarify intent/completeness of initial staging surgery (omentectomy, peritoneal biopsies, lymph nodes, washings) and final FIGO stage – currently unknown.  \n- Obtain full current pelvic/abdominal imaging report (including latest MRI with 1.8 cm nodule) and any FAPI schedule/results.  \n- Continue systemic therapy planning as first‑line adjuvant/continued treatment, coordinating with fertility-sparing goals and potential delayed conservative surgery.  \n- Monitor AFP, LDH, β‑hCG, CA125, NSE trends; β‑hCG, LDH, full tumour marker panel currently undocumented and need updating.&quot;,
  &quot;oncologist&quot;: &quot;- Post-op mixed germ cell tumour with teratomatous component; fertility-sparing approach with residual left ovary requires careful staging confirmation (imaging/pathology).  \n\n- Two cycles of first-line cisplatin-based combination completed; current treatment phase likely still primary/adjuvant rather than relapse therapy.  \n\n- AFP normalized after chemotherapy, suggesting good marker response; CA125 and NSE roles as disease markers remain uncertain and need correlation.  \n\n- Key missing: detailed pathology report (stage, margins, risk factors, teratoma maturity) and full imaging description of left ovarian nodule.  \n\n- Also needed: current organ function (renal, pulmonary, marrow), toxicity history, and MDT fertility goals before deciding further cycles vs surveillance/surgery.&quot;,
  &quot;radiologist&quot;: &quot;- Left ovarian surface solid nodule 1.8 cm, extra-surface location, suspicious for implantation deposit. [@Role-Specific-Case-View|Unknown]  \n\n- Nodule has decreased in size compared with prior imaging, suggesting partial interval response/improvement. [@Role-Specific-Case-View|Unknown]  \n\n- Postoperative pelvic changes with residual mass; precise size, margins, and composition not fully characterized. Needs updated cross-sectional imaging. [@Role-Specific-Case-View|2024-09-28]  \n\n- Small pelvic effusion present; clinical significance and evolution uncertain without follow-up imaging. [@Role-Specific-Case-View|2024-09-27]  \n\n- No PET/FAPI or contemporaneous whole-abdomen imaging available; staging and extra-pelvic disease assessment need updated CT/MRI ± PET.&quot;,
  &quot;pathologist&quot;: &quot;- Diagnosis: Right ovarian mixed germ cell tumour, predominantly dysgerminoma with ~10% mature teratoma; necrosis and vascular proliferation present [@HISTOLOGY_AND_IHC|2024-09-02].  \n- IHC profile (SALL4, Oct4, PLAP, D2-40, CD117 positive; AFP, GPC3, CD30 negative) strongly supports dysgerminoma; no yolk sac component [@HISTOLOGY_AND_IHC|2024-09-02].  \n- Proliferation index high (Ki-67 ~80%), consistent with biologically active dysgerminoma component [@HISTOLOGY_AND_IHC|2024-09-02].  \n- Current biomarkers: serum AFP &lt;2; CA125 mildly elevated; no HER2, MSI, PD-L1, or TMB data [@MOLECULAR|2024-10-22].  \n- Missing for complete pathology staging: tumour size, capsule status, surface involvement, nodal/extraovarian sampling, FIGO stage, margin status—needs surgical/pathology update.&quot;,
  &quot;nuclear&quot;: &quot;- No PET-CT reports available; metabolic status of the left adnexal/ovarian surface lesion is unknown/needs update.  \n\n- Prior imaging suggests left adnexal/ovarian surface solid nodule, possibly implantation, but without metabolic characterization. [@IMAGING_CONTEXT|Unknown]  \n\n- PET (FDG or FAPI per protocol) could help distinguish post-operative change from metabolically active residual or recurrent disease.  \n\n- PET findings could upstage disease if additional hypermetabolic peritoneal/implantation sites or nodal involvement are identified beyond current CT impressions.  \n\n- Request updated PET-CT (or FAPI-PET if available) report to refine staging and recurrence suspicion at/after this visit date.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Defer additional chemotherapy until FIGO stage, left ovarian lesion characterization, organ function, and fertility goals are clarified (all currently unknown).  \n- Obtain full operative/pathology reports to define tumour size, capsule/surface, washings, omentum, nodes, margins, final stage (all unknown).  \n- Arrange updated contrast-enhanced CT/MRI abdomen–pelvis ± chest plus PET/FAPI at a single staging timepoint to assess lesion and spread.  \n- Standardize serial markers (AFP, β‑hCG, LDH, CA125, NSE) with dates and integrate with imaging for response assessment (current series incomplete/unknown).  \n- Re-discuss in MDT after pathology/imaging/marker update to decide between continued first‑line systemic therapy and fertility-sparing delayed surgery sequencing.&quot;,
    &quot;oncologist&quot;: &quot;- Defer additional systemic therapy decisions until full operative/pathology staging details and FIGO stage are obtained (currently unknown).  \n\n- Arrange updated contrast-enhanced CT/MRI abdomen–pelvis ± chest to reassess left ovarian nodule and search for extra‑pelvic disease (none documented).  \n\n- Coordinate PET/FAPI with next cross‑sectional imaging after current chemotherapy cycle or pre-surgery to characterize the left ovarian lesion and staging.  \n\n- Implement serial tumour marker panel (AFP, β‑hCG, LDH, CA125, NSE) with dates; β‑hCG and LDH currently unknown.  \n\n- Document renal, pulmonary, marrow function and prior toxicities post-BEP (all currently unknown), and clarify patient fertility goals before finalizing regimen.&quot;,
    &quot;radiologist&quot;: &quot;- Obtain updated contrast-enhanced CT or MRI abdomen–pelvis ± chest to restage and fully characterize the 1.8 cm left ovarian nodule. [@Role-Specific-Case-View|Unknown]  \n\n- Schedule PET/FAPI (if available) coordinated with this cross-sectional study to assess metabolic activity and detect extra-pelvic disease. [@Role-Specific-Case-View|Unknown]  \n\n- On new imaging, document precise nodule size trend, enhancement, diffusion, and relation to ovarian cortex/peritoneal surface for implantation assessment. [@Role-Specific-Case-View|Unknown]  \n\n- Systematically evaluate for additional peritoneal/omental implants and quantify pelvic effusion volume and characteristics on updated imaging. [@Role-Specific-Case-View|2024-09-27]  \n\n- Reconcile new imaging with operative/pathology staging once available to support definitive FIGO stage assignment and surgical planning. [@Role-Specific-Case-View|Unknown]&quot;,
    &quot;pathologist&quot;: &quot;- Confirm full surgical and pathology staging details, including capsule/surface status, peritoneal/omental biopsies, nodes, washings, margins, FIGO stage [@HISTOLOGY_AND_IHC|2024-09-02].  \n- Re-review original slides to document teratoma maturity, any extraovarian tumour, and precise dysgerminoma/teratoma proportions [@HISTOLOGY_AND_IHC|2024-09-02].  \n- Correlate serial AFP, β‑hCG, LDH, CA125, NSE trends with imaging once complete marker timeline is available (currently incomplete; needs update).  \n- After updated CT/MRI and PET/FAPI, jointly reassess left ovarian surface nodule as active implant vs teratoma vs benign change (imaging reports pending).  \n- Defer pathology-based advice on further systemic therapy or delayed surgery until staging and lesion characterization are finalized (data currently insufficient).&quot;,
    &quot;nuclear&quot;: &quot;- No prior PET or FAPI imaging; metabolic activity of the left ovarian surface nodule remains unknown/needs update.  \n\n- Decreasing 1.8 cm left ovarian surface nodule suggests possible treatment response but etiology (implant vs teratoma vs reactive) remains indeterminate. [@IMAGING_CONTEXT|Unknown]  \n\n- Whole-body PET (FDG or FAPI per protocol) combined with next CT/MRI could newly define extra‑pelvic disease and refine FIGO staging.  \n\n- PET at a unified post-chemotherapy staging timepoint may distinguish active implantation from benign/postoperative change, directly impacting recurrence suspicion.  \n\n- Recommend scheduling PET/FAPI alongside the next contrast-enhanced abdomen–pelvis study once current chemotherapy cycle is completed or before major surgery.&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Before changing therapy, obtain full operative/pathology staging details and FIGO stage assignment; current extent of disease is unknown.  \n- Arrange updated contrast-enhanced CT/MRI abdomen–pelvis ± chest with focused characterization of the left ovarian nodule and peritoneum.  \n- Coordinate same-session whole‑body PET/FAPI with CT/MRI after current BEP course to stage globally and assess the left nodule.  \n- Clarify patient’s fertility goals and current BEP toxicities (renal, pulmonary, marrow, otologic) to guide intensity of further chemo vs surgery.  \n- Implement standardized serial markers (AFP, β‑hCG, LDH, CA125, NSE) with dates, interpreted jointly with imaging for response/surveillance.&quot;,
    &quot;oncologist&quot;: &quot;- Systemic therapy remains first-line/adjuvant; further cycles should await clarified FIGO stage and staging completeness (operative/pathology details currently unknown).  \n\n- Arrange updated contrast-enhanced CT/MRI abdomen–pelvis ± chest plus whole‑body PET/FAPI in a single post‑BEP staging session (extra‑pelvic status unknown).  \n\n- Request pathology addendum detailing tumour size, capsule/surface involvement, washings, extraovarian disease, teratoma maturity, and FIGO stage (all currently unknown).  \n\n- Implement standardized serial tumour markers (AFP, β‑hCG, LDH, CA125, NSE) with dates; β‑hCG and LDH values are unknown.  \n\n- Document renal, pulmonary, marrow function, ototoxicity after BEP and patient fertility priorities before finalizing systemic‑therapy versus delayed conservative surgery strategy.&quot;,
    &quot;radiologist&quot;: &quot;- Restage with contrast-enhanced CT or MRI abdomen–pelvis ± chest to characterize the 1.8 cm left ovarian surface nodule. [@Role-Specific-Case-View|Unknown]  \n\n- Coordinate same-session whole-body FDG-PET or FAPI-PET with this CT/MRI after current BEP cycle for global metabolic staging. [@Role-Specific-Case-View|Unknown]  \n\n- On new imaging, document nodule size trend, enhancement, diffusion, and cortex/peritoneal relationship to distinguish implantation from benign/postoperative change. [@Role-Specific-Case-View|Unknown]  \n\n- Systematically assess peritoneum/omentum for additional implants and better quantify/characterize pelvic effusion on updated imaging. [@Role-Specific-Case-View|2024-09-27]  \n\n- Integrate new imaging findings with forthcoming operative/pathology details to support FIGO staging and fertility-sparing surgical planning. [@Role-Specific-Case-View|Unknown]&quot;,
    &quot;pathologist&quot;: &quot;- Confirm and document tumour size, capsule/surface status, washings, margins, nodal/peritoneal/omental sampling, and FIGO stage in an addendum [@HISTOLOGY_AND_IHC|2024-09-02].  \n- Review all blocks to re-verify absence of yolk sac/other malignant germ cell elements and to grade teratoma maturity [@HISTOLOGY_AND_IHC|2024-09-02].  \n- State explicitly whether any extraovarian tumour was present in the right adnexa specimen or associated tissues (currently unknown) [@HISTOLOGY_AND_IHC|2024-09-02].  \n- Correlate pathology with updated imaging of the left ovarian surface lesion to suggest most likely nature (implant vs teratoma vs benign).  \n- Refrain from further pathology-based recommendations on chemotherapy or surgery until staging addendum and new imaging/markers are available (data incomplete).&quot;,
    &quot;nuclear&quot;: &quot;- No prior PET/FAPI; metabolic status of the 1.8 cm left ovarian surface nodule remains unknown/needs update.  \n\n- MRI shows a decreasing 1.8 cm left ovarian surface nodule with small pelvic effusion; etiology remains indeterminate (implant vs benign). [@IMAGING_CONTEXT|Unknown]  \n\n- Plan whole‑body FDG‑PET (or FAPI if available) combined with next contrast CT/MRI after current BEP cycle for unified staging.  \n\n- PET can clarify extra‑pelvic disease burden and refine FIGO staging by detecting occult peritoneal/omental implants not yet characterized.  \n\n- Metabolic activity pattern in the left ovarian lesion will help distinguish viable implantation from postoperative/inflammatory or teratomatous change, informing recurrence risk.&quot;
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Selected Clinical Context (JSON)</summary>
    <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>Ovarian mixed germ cell tumor (dysgerminoma + mature teratoma), post-first-line BEP, platinum-sensitive with residual left adnexal/pelvic implant-suspected mass; high Ki-67 (~80%); no reported metastases, molecular markers, or major organ/functional constraints.</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>RAG Evidence Pack (top=5):
[1] score=0.6252 esmo_cpg_nonepithelialovarian_2018__v00000000 [PAGE 13]
    nately, none of them has been compared with BEP in randomised trials. A phase II Gynecologic Oncology Group (GOG) trial reported high activity with an acceptable toxicity proﬁle for a carboplatin–etoposide combination in the adjuvant setting of completely resected stages I–III dysgerminomas [40]. Dy…
[2] score=0.6157 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17]
    to the use of ovarian preservation itself and/or the natural history of the disease (whatever the preservation or not of the ovary) in these patients having poorest prognostic factors). 1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac tumours; 3well and moderat…
[3] score=0.6060 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 8]
    [III, B]. Consensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35 voters) Recommendation 11.7: Contrast-enhanced CT, MRI and PETeCT with a structured radiology report are considered as options for the initial evaluation of patients with advanced ovarian carcinoma [III, A]. US by an expert so- nograph…
[4] score=0.5973 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 11]
    MEK inhibitor trametinib should be considered after prior platinum-based ChT and hormone therapy (not EMA approved) [I, A]. FOLLOW-UP, LONG-TERM IMPLICATIONS AND SURVIVORSHIP Surveillance Although a cure is unlikely after relapse, effective therapies exist for the treatment of patients with recurren…
[5] score=0.5961 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10]
    with ﬁrst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected …</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6251811981201172,
    &quot;doc_id&quot;: &quot;esmo_cpg_nonepithelialovarian_2018__v00000000&quot;,
    &quot;page&quot;: 13,
    &quot;text&quot;: &quot;nately, none of them has been compared with BEP in randomised\ntrials. A phase II Gynecologic Oncology Group (GOG) trial\nreported high activity with an acceptable toxicity proﬁle for a\ncarboplatin–etoposide combination in the adjuvant setting\nof completely resected stages I–III dysgerminomas [40].\nDysgerminomas are very sensitive to RT; however, its use is lim-\nited to selected cases because of the negative impact on fertility.\nIn patients with platinum-sensitive relapse (progression\n&gt; 4–6 weeks after completion of ChT), ifosfamide/platinum (IP)\nwith or without paclitaxel (P) should be considered as second-\nline treatment [IV, C] [41]. Further active ChT regimens include:\nvinblastine/ifosfamide/cisplatin (VeIP) and cisplatin/vinblastine/\nbleomycin (PVB) [IV, C] [42]. Patients resistant to a cisplatin-\nbased combination may receive vincristine/actinomycin D/cyclo-\nphosphamide (VAC) or paclitaxel/gemcitabine or gemcitabine/\noxaliplatin as salvage therapy [IV, C].\nAlthough there is a role for ASCT in relapsed testicular cancer, it\nis not the standard of care for women with relapsed or recurrent\nmalignant ovarian GCTs and its role remains undeﬁned because of&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6157110333442688,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;to the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).\n1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac\ntumours; 3well and moderately differentiated; 4poorly differentiated; #for grade 2-3 imma-\nture teratoma stage II-IV, fertility-sparing data are limited; ## for Sertoli-Leydig cell tumour\nstage IC2-3, fertility-sparing data are limited.\nBOT borderline ovarian tumour; CCC clear cell carcinoma; GCT germ cell tumour; GrCT\ngranulosa cell tumour; HGEC high-grade endometrioid carcinoma; HGSC high-grade serous\ncarcinoma; LGSC low-grade serous carcinoma; LGEC low-grade endometrioid carcinoma,\nMCexp mucinous carcinoma with expansile invasion, MCinf mucinous carcinoma with in-\nfiltrative invasion; SCC small cell carcinoma; SLCT Sertoli-Leydig cell tumour.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6059778928756714,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 8,
    &quot;text&quot;: &quot;[III, B].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35\nvoters)\nRecommendation 11.7: Contrast-enhanced CT, MRI and\nPETeCT with a structured radiology report are considered\nas options for the initial evaluation of patients with\nadvanced ovarian carcinoma [III, A]. US by an expert so-\nnographer may be used to assess tumour extent and\nresectability in the pelvis and abdominal cavity [III, C].\nJ. A. Ledermann et al.\nAnnals of Oncology\nVolume 35&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.5973372459411621,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;MEK inhibitor trametinib should be considered after\nprior platinum-based ChT and hormone therapy (not\nEMA approved) [I, A].\nFOLLOW-UP, LONG-TERM IMPLICATIONS AND\nSURVIVORSHIP\nSurveillance\nAlthough a cure is unlikely after relapse, effective therapies\nexist for the treatment of patients with recurrent ovarian\ncancer. Therefore, surveillance in these patients is indicated\nwith a combination of thorough symptom review and\nphysical examination. Studies have noted that 26%-50% of\nrecurrences are in the pelvis97 suggesting a role for pelvic\nexamination in the follow-up of ovarian cancer. Disease\nrecurrence, however, may be located outside of the pelvis,\ne.g. in lymph nodes, liver, lungs or peritoneal carcinoma-\ntosis and may not be detectable by pelvic examination. CT\nscans have been noted to have a sensitivity of 79% and\nspeciﬁcity of 84% for detecting relapse in a large pooled\nmeta-analysis.98 CT scans are indicated if symptoms suggest\nrecurrent disease or if the CA-125 is rising.98\nCA-125 has been evaluated in the surveillance of ovarian\ncancer and has been noted to be elevated 2-5 months\nbefore radiographic detection of cancer. In a large pro-&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.5961059331893921,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- Carboplatin–etoposide is an active adjuvant option with acceptable toxicity for completely resected stage I–III dysgerminoma, based on a GOG phase II trial; however, it has not been directly compared with BEP in randomized studies [1].  
- Fertility-sparing surgery (with ovarian preservation) is an established option in selected malignant ovarian germ cell tumours, including dysgerminoma, yolk sac tumour, and immature teratoma, provided oncologic safety is ensured and risk factors are considered [2].  
- In advanced ovarian carcinoma, initial staging and treatment planning can use contrast-enhanced CT, MRI, or PET-CT, and expert transvaginal ultrasonography; reports should be structured to aid MDT decisions [3].  
- In recurrent epithelial ovarian cancer, choice between PARP inhibitors and anti-VEGF therapy at relapse should consider histologic subtype, BRCA1/2 mutation status, prior exposure to PARPi and/or bevacizumab, and expected toxicities [5].  
- Cumulative platinum exposure and prior lines of therapy influence both efficacy and toxicity in subsequent platinum-based treatments for relapsed epithelial ovarian cancer, and should guide regimen selection [5].  
- For low-grade serous ovarian carcinoma, the MEK inhibitor trametinib can be considered after prior platinum-based chemotherapy and hormone therapy, though it is not EMA approved and should be weighed against alternatives and access issues [4].  
- In relapsed epithelial ovarian cancer, long-term surveillance should balance the low likelihood of cure with the availability of effective therapies, integrating symptom assessment, imaging, and tumour markers to guide timely intervention [4].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-18T00:44:58.941281&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2024-10-29 15:38:50.183000&quot;,
      &quot;meta_info&quot;: &quot;361127200904290341&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:44:58.941564&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;1a87e77867d4&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:44:59.241286&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 0,
      &quot;img_n&quot;: 0,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 0,
      &quot;cutoff_dt&quot;: &quot;2024-10-30 15:38:50&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:44:59.300134&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:45:32.893410&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Ovarian mixed germ cell tumor (dysgerminoma + mature teratoma), post-first-line BEP, platinum-sensitive with residual left adnexal/pelvic implant-suspected mass; high Ki-67 (~80%); no reported metastases, molecular markers, or major organ/functional constraints.&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:45:32.893418&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:45:39.437726&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:49:37.966829&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 4151
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:49:37.968371&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T00:49:41.492405&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1409
    }
  }
]</pre>
  </details>

</body>
</html>
